Maximum Views Reached

You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.

To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.

Management of Opioid Use Disorder (2024 CRISM Guideline)

Publication Date: November 12, 2024

Last Updated: November 13, 2024

Summary of Recommendations

Buprenorphine and methadone should both be considered as standard first-line treatment options for opioid agonist therapy.

For people who initiate opioid agonist therapy with buprenorphine, clinicians should be aware of the higher risk of attrition after the first month of initiation and offer alternative opioid agonist medications in these circumstances (high certainty).
When considering methadone, clinicians should be aware of the higher risk of mortality during the first month compared with the remainder of the treatment period (moderate certainty).

(S, H )

620

Overview

Title

Management of Opioid Use Disorder (2024 CRISM Guideline)

Authoring Organization